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A B S T R A C T
Tumour-associated macrophages (TAM) are forced by cancer cells to adopt an anti-inflammatory phenotype and
secrete factors to promote tumour invasion thus being responsible for poor patient outcome. The aim of this
study is to develop a clinically applicable, non-invasive method to obtain a quantitative TAM detection in tu-
mour tissue. The method is based on longitudinal proton relaxation rate (R1) measurements at low field
(0.01–1 MHz) to assess the localization of ferumoxytol (clinical approved iron oxide particles) in TAM present in
melanoma tumours, where R1 = 1/T1. R1 at low magnetic fields appears highly dependent on the intra or extra
cellular localization of the nanoparticles thus allowing an unambiguous TAM quantification. R1 profiles were
acquired on a Fast Field-Cycling relaxometer equipped with a 40 mm wide bore magnet and an 11 mm solenoid
detection coil placed around the anatomical region of interest. The R1 values measured 3 h and 24 h after the
injection were significantly different. At 24 h R1 exhibited a behavior similar to “in vitro” ferumoxytol-labelled
J774A.1 macrophages whereas at 3 h, when the ferumoxytol distribution was extracellular, R1 exhibited higher
values similar to that of free ferumoxytol in solution. This finding clearly indicated the intracellular localization
of ferumoxytol at 24 h, as confirmed by histological analysis (Pearls and CD68 assays). This information could be
hardly achievable from measurements at a single magnetic field and opens new horizons for cell tracking ap-
plications using FFC-MRI.
1. Introduction
The complex relationships between the immune system and the
tumour are under intense scrutiny as they are considered an important
hallmark of cancer [1]. Tumour-associated macrophages (TAM) are
forced by the cancer cells to adopt an anti-inflammatory phenotype and
secrete factors to promote angiogenesis and tumour invasion [2]. For
these reasons, sensitive, non-invasive, methods capable of quantitative
TAM detection are needed for tumour characterization and individual
patient stratification to therapies aimed at TAM elimination or polar-
ization to the M1 phenotype with antitumour properties [3–5]. Among
imaging modalities, Magnetic Resonance Imaging (MRI) had a key role
in the field of oncology over the last few decades. The prominent role of
MRI relies on its superb spatial and temporal resolution; its diagnostic
power arises basically from the differences in the longitudinal (T1) and
transverse (T2 and T2*) proton relaxation times between healthy and
pathological tissues. However, routine MRI assessments are often not
able to report on the early tissue changes occurring in response to
therapeutic treatments [6].
In this context, the use of Ultrasmall Superparamagnetic Iron Oxides
NanoParticles (USPIO-NPs) was proposed in many studies because they
are taken up by TAM, generating a detectable contrast in T2-and T2*
-weighted images [7–10]. However the main drawback of this approach
is that the observed contrast is unable to discriminate between extra-
and intra-cellular USPIO-NPs and it is therefore biased by non-inter-
nalized particles. Therefore, there is a need to develop methods sensi-
tive to the localization of NPs. Of course, the applications under con-
sideration not only involves TAM detection but also includes a number
of “cell tracking” applications. In fact, there is an open discussion re-
garding the advantage of imaging protocols to improve the in vivo
monitoring of cell therapies [11,12].
Recently, ferumoxytol, a USPIO-NP commercialized for the
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treatment of anemia in adult patients, has attracted interest for clinical
imaging applications [13]. Ferumoxytol is a superparamagnetic iron
oxide nanoparticle with a hydrodynamic diameter of 30 nm coated with
a semi-synthetic low molecular weight carbohydrate shell (precisely, a
polyglucose sorbitol-carboxymethylether shell) [14,15]. The core is
consistent with a cubic maghemite (γ-Fe2O3) crystal structure, irregular
in shape and with a mean diameter of approximately 3.25 nm, as shown
by the TEM morphological analysis [14].
USPIO particles were extensively used as contrast agents for MRI as
they have several advantages over standard small molecular para-
magnetic contrast agents including: i) higher relaxivity, leading to
higher sensitivity; ii) specificity to target tumour region delivery via the
enhanced permeability and retention (EPR) effect [16]; iii) ability to be
phagocytosed by cells of the Reticulo Endothelial (RES) and Mono-
nuclear Phagocyte (MPS) systems [17]. Intravenously injected USPIO-
NPs distribute in the blood pool and, due to their large size, remain
confined to the intravascular space in most organs, except for liver and
spleen. In tumours, ferumoxytol slowly extravasates across the highly
permeable endothelium of tumour, accumulates in the tumour stroma
where it may be phagocytosed by TAM [18–21]. It has been reported
that extracellular iron oxides in early tumour necrosis lead to strong T1
and T2-enhancement at high (> 3 T) magnetic field while compart-
mentalized intracellular iron oxides in macrophages are characterized
by predominant T2-with little T1-enhancement [22,23]. Therefore,
these USPIO-NPs were proposed for the quantification of necrotic zones
and/or macrophages infiltrating tumour stroma that highly correlate
with poor outcome.
Herein, we propose a new alternative diagnostic protocol to assess
the localization of ferumoxytol in TAM in melanoma tumours. The
method is based on the measurement of proton relaxation rate R1,
where R1 = 1/T1, as a function of the magnetic field strength (Nuclear
Magnetic Resonance Dispersion, NMRD, profile), by using a Fast Field
Cycling (FFC) relaxometer. FFC is the only practical way of measuring
T1-dispersion and involves rapid switching of the magnetic field be-
tween different field strengths during the measurement procedure.
Recently, the prognostic potential of the NMRD profile has been high-
lighted by our group, using an FFC-relaxometer prototype endowed
with a wide-bore magnet and a dedicated transmitter/receiver solenoid
detection coil of 11 mm diameter placed around a mouse's leg. Water
proton 1/T1 NMRD profile measured in vivo on implanted mammary
tumours showed a marked T1 elongation at low magnetic fields
(< 0.2 T) with respect to healthy tissues [24–26]. Recently, two pro-
totypes human whole-body sized Fast Field Cycling-MRI scanners built
at the University of Aberdeen by Lurie's group allowed in vivo mea-
surements on human patients thus demonstrating the possibility of
translating the preclinical results to clinic. Both instruments can change
the magnetic field strengths, between 1 mT and 100 mT in 30 ms for
our system and 0.1 mT–200 mT in 15 ms for the Aberdeen FFC-MRI
scanner [27]. Pilot studies performed on these FFC-MRI scanners have
already demonstrated the potential use of FFC-MRI in a range of several
pathologies such us musculoskeletal and cardiovascular diseases
[28,29]. Herein we report that ferumoxytol effect on tissue relaxation
rates at low magnetic field strengths (0.01–1 MHz as expressed in terms
of the corresponding proton Larmor frequencies) is highly dependent
on the intracellular or extracellular localization of the magnetic parti-
cles thus allowing an unambiguous TAM quantification. Likely, the
method can be generalized to other USPIO-NPs, in particular to those
characterized by a relatively low R2/R1 ratio.
2. Materials and methods
2.1. Cell cultures
B16–F10 (ATCC® CRL-6475™) and J774A.1 (ATCC® TIB-67™) were
purchased from American Type Culture Collection (ATCC, USA). They
were grown in Dulbecco's modified Eagle's media supplemented with
10% fetal bovine serum (FBS), 100U/mL Penicillin (P) with 100 μg/ml
Streptomycin (S). Cells were cultured in 5% CO2/95% air at 37 °C in a
humidified chamber, split every 2–3 days, and used up to passage 10.
All cells were tested negative for mycoplasma by MycoAlert™
Mycoplasma Detection Kit. All materials were purchased from Lonza
(Basel, Switzerland).
2.2. Ferumoxytol uptake by J774A.1 macrophage and in vitro NMRD
profile
For experiments of uptake, 500,000 of J774A.1 were plated in 6 cm
dishes 24 h before the incubation with different concentration of
Ferumoxytol (Takeda Pharma A/S Roskilde, Danmark) (from 0.06 to
1 mM of Fe). The amount of Fe was measured by ICP-MS procedure, as
described below. For NMRD profile experiments, 2 million of J774A.1
were plated and the day after they were incubated in presence of 0.5
and 0.1 mM of Fe for 24 h. The cells were detached with scraper and
washed three times with 20 ml of PBS. Then the cell suspension was
transferred in the NMR glass tube and the pellet was obtained removing
the supernatant after 5 min of centrifugation (0.1 rcf), just before the
NMRD profile acquisition. The 1H-NMRD profiles were measured over a
range of magnetic field strength from 0.01 to 10 MHz proton Larmor
frequency on the Fast-Field Cycling relaxometer (SmartTracer, Stelar S.
r.l., Mede (PV)). The typical field sequences used were the Not
Polarized (NP) sequence between 10 and 7.5 MHz and the Pre Polarized
(PP) sequence between 7.5 and 0.01 MHz. The observation field was set
at 7.2 MHz T1 was determined by the saturation recovery method.
Sixteen values of delay (τ) between pulses were used. The number of
averaged experiments was two.
2.3. Animal model
6-old-week male C57BL/6 mice were inoculated in muscle hind
limb with 750,000 B16–F10 cells in 100 μL of PBS. C57BL/6 (Charles
River Laboratories Italia S. r.l., Calco Italia) were maintained under
specific pathogen-free conditions in the animal facility of the Molecular
Biotechnology Center, University of Turin. All animal experiments have
been carried out in accordance with the EU Directive 2010/63/EU for
animal experiments. Before imaging and nuclear magnetic resonance
experiments, mice were anaesthetized with a mixture of tiletamine/
zolazepam (Zoletil 100; Vibac, Milan, Italy) 20 mg/kg and xylazine
(Rompun; Bayer, Milan, Italy) 5 mg/kg. The animal treatment protocol
was approved by the Italian Ministry of Health (Authorization number
807/2017-PR).
2.4. In vivo NMRD profiles acquisition
1H-NMRD profiles were acquired on a Stelar SPINMASTER FFC
NMR relaxometer (Stelar S.r.l., Mede (PV), Italy). Data were acquired
with the NP sequence (10 MHz ≤ relaxation field ≤ 7 MHz) or the PP
sequence (relaxation field < 7 MHz). The relaxometer operates under
complete computer control with an absolute uncertainty in the 1/T1
value of± 2%.
1/T1 NMRD profiles of tumour-bearing mouse (8 points at 0.01,
0.019, 0.037, 0.07, 0.15, 0.387, 1 and 10 MHz) were acquired when the
tumour mass was>65% of the total leg using the relaxometer
equipped with a 40 mm 0.5 T FC magnet and a dedicated 11 mm so-
lenoid detection coil. Data were acquired with the above-mentioned
sequences with polarization at 13 MHz and detection at 14.5 MHz, a
field switching time of 4 ms, a 90° pulse length of 5.5 μs. Thirty-two
incremented relaxation delay were logarithmic distributed from 0.01 to
2.8 s for the points in the field range 0.01–0.07 MHz and from 0.01 to
4 s for the points in the field range 0.15–10 MHz.
The NMRD profiles were carried out before (PRE), 3 and 24 h after
(POST) the ferumoxytol injection (0.5 mmol/kg dose of Fe).
The magnetization recovery data were analysed according to a
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mono-exponential decay (Bloch equation) and the two-Site eXchange
model (2SX model, see below) with Origin software (OriginPro 8.5.0
SR1, OriginLab, Northampton, MA, Levenberg-Marquardt algorithm).
2.5. Immunochemistry assay
Immediately after the NMRD profile, the mice were sacrificed and
perfused via the vascular system with 4% paraformaldehyde (PFA), as
fixation procedure, in order to obtain the best possible preservation of
the tumour tissue for immunohistochemistry [30].
PFA-fixed and paraffin-embedded tissue sections were stained with
haematoxylin & eosin. For immunohistochemistry assays, de-waxed
5 μm sections were submitted to wet heat-induced antigen retrieval in a
mixture of 0.1 M Tris and 0.01 M EDTA solution at pH 9.0. Endogenous
peroxidase was blocked in 0.6% hydrogen peroxide solution in 0.05 M
TBS (pH 7.6) for 20 min at room temperature. Sections were then
treated with 5% normal goat serum and reacted overnight with rabbit
anti-mouse CD68 (ab125212; Abcam). Subsequently, sections were in-
cubated with goat anti-rabbit (ab97051; Abcam) IgG conjugated to HRP
for 1 h at room temperature. Finally, sections were treated with dia-
minobenzidine-enhanced liquid substrate chromogen system (D3939;
Sigma-Aldrich) and counterstained with haematoxylin.
For Perls staining, tissue sections were de-waxed and treated with a
solution of 5% potassium ferrocyanide and 5% hydrochloric acid for
1 h at room temperature. Finally, sections were counterstained with
Nuclear Fast Red solution (Sigma).
For CD68 and Perls staining on the same tissue section, CD68 IHC
was performed as stated above. After incubation with secondary anti-
body conjugated to HRP, sections were treated with AEC substrate
(Abcam) and mounted with glycerol. Several images were acquired
with optical microscope (Olympus BX41). Then cover glasses were re-
moved and slides were rinsed in alcohol 99% and xylene in order to
dissolve AEC substrate. Finally, the same slides were used for Perls
staining, counterstained with Nuclear Fast Red solution and mounted in
synthetic mounting. Perls images of the same section were acquired as
above. Images of the same region were overlapped with ImageJ soft-
ware in order to obtain a merge of the two staining techinques (CD68
and Perls).
2.6. Inductively coupled plasma mass spectrometry (ICP-MS)
Fe content from cell samples and ferymoxytol solutions were de-
termined using inductively coupled plasma mass spectrometry (ICP-
MS) (Element-2; Thermo-Finnigan, Rodano (MI), Italy). Sample diges-
tion was performed by means of microwave heating for 10 min at
160 °C in 1 mL of concentrated HNO3 (70%) (Milestone, Ethos Up
Microwave Digestion System, Bergamo, Italy). A natural abundance
iron standard solution was analysed during sample runs in order to
check for variations in the systematic bias. The calibration curve was
obtained using four iron absorption standard solutions (Sigma-Aldrich)
in the range 0.2–0.005 μg/mL.
2.7. The two-site eXchange (2SX) model
In the two-Site eXchange (2SX) model, the Bloch equations for nu-
clear magnetic resonance were modified to describe two compartments
(intra and extracellular) in which water exchange modulates the ob-
served relaxation behavior [31–34]. The time evolution of MZ depends
on the absolute values of the relative size of the “relaxation” term, |R1in
- R1ex|, and of the “exchange” term kin+ kex, (where kin = 1/τin is the
water exchange rate from the extracellular to the intracellular com-
partment and kex = 1/τex is the water exchange rate in the opposite
direction). This relationship was previously defined as the NMR
“shutter-speed”.
The PRE data were simultaneously analysed, sharing the Vex and τin
parameters but maintaining R1ex fixed to the value obtained from
Matrigel in a separated experiment, in order to reduce the number of
parameters to fit [24]. The parameter Vex was allowed to vary within a
reasonable range, in accordance with results already reported in the
literature (0.15–0.5) for tumour mouse hind-limb [35–37].
In the case of the NMRD profiles acquired 24 h after the ferumoxytol
injection, the R1in term is expressed as follows:= +R R Fe[ ] rin in1 10 1 (1)
where R1in0 is the contribution in the absence of ferumoxytol, [Fe] and
r1 are the ferumoxytol intracellular concentration (calculated from the
contrasted images acquired at 7 T, as described above) and relaxivity,
respectively. The R1in0, Vex and τin values were fixed at the values found
in the analysis of the corresponding PRE-contrast NMRD profiles.
2.8. Magnetic Resonance Imaging (MRI)
MR images of the mouse limb region were acquired on a 7 T Bruker
AV300 spectrometer equipped with a Micro 2.5 microimaging probe
and a birdcage resonator with 30‐mm inner diameter. Images were
recorded the same day as the acquisition of the NMRD profiles before
and after the injection of ferumoxytol (0.5 mmol/kg of Fe). The dis-
tribution of ferumoxytol in the tumour region was followed by mea-
suring T1 by means of a saturation recovery sequence (TE = 3.3 ms;
number of slices = 3; slice thickness = 2 mm; FOV 30 × 30 mm;
matrix 32 × 32), before, 3 h and 24 h after injection of the contrast
agent. The tumour volume was measured from T2-weighted MRI images
obtained by using a rapid acquisition with refocused echoes sequence
protocol (TR = 5000 ms; TE = 28 ms; number of slices = 11; slice
thickness = 1 mm; FOV 50 × 50 mm; matrix 168 × 160).
Assuming the occurrence of a fast-exchange regime (i.e., |R1in −
R1ex| « kin+ kex) [38] at 7 T, the effective intratumour Fe concentration,
[Fe]eff, was determined by Equation (2)= = =Fe R R r R r i[ ] ( )/ / with in or exeff POST PRE i i1 1 1 1 1 (2)
where R1POST and R1PRE are the relaxation rates measured after and
before ferumoxytol injection; r1ex is the millimolar relaxivity of fer-
umoxytol, measured at 7 T, in Matrigel (used as extracellular matrix
model, r1ex = 2.4 mM−1 s−1); r1in is the millimolar relaxivity of fer-
umoxytol, measured at 7 T, on J774A.1 cells incubated for 6 h with
ferumoxytol dissolved in the culture medium at a 0.02 mM Fe con-
centration (r1in = 1.05 mM−1 s−1). After incubation cells were washed
three times with cold PBS, detached with scraper, transferred into the
5 mm NMR tube and centrifuged 5 min at 0.1 rcf. Fe concentration
remaining into the cell pellet was determined by ICP-MS.
The [Fe]eff is the effective value of the tissue concentration, as it
refers to the sum of the intracellular and extracellular volumes. Then,
the Fe concentration in the extracellular and intracellular volume
fraction (Vi) is given by Equation (3)= =Fe Fe V i[ ] [ ] / with in or exi eff i (3)
2.9. Calculation of the fraction of macrophages in the tumour tissue
The equation for the calculation of macrophage fraction was derived
as following:
= ×number of TAM
total cell number in the tissue
% TAM in tumour tissue 100
(4)
where the total number of cells in 1 g of tissue was considered to be 109
[39]. The number of TAM in 1 g of tissue was expressed as
= mmol of Fe in g
mmol of Fe per TAM cell
Number of TAM in 1 g of tissue 1
(5)
where the quantity of iron in mmol in 1 g is:


















where the mmol of Fe per TAM cell was calculated using J774A.1 in-
cubated 24 h in the presence of ferumoxytol 0.005 mM. After cell
washing and detaching Fe was determined by ICP-MS and normalized
to the cell number. The 0.005 mM ferumoxytol concentration was used
because the corresponding r1 at 1 MHz (7 mM−1 s−1) equal to that
found in tumour tissue in vivo.
Equation 7 is obtained by combination of equations (4)–(6):
= + × ×mmols of Fe per cell% TAM in tumour tissue ( R 0.41) 7 10h124 10 (7)
2.10. Isolation of mouse tumour-associated macrophages (TAM)
After the acquisition of 1/T1 NMRD profile at 24 h post ferumoxytol
injection, the protocol for the isolation of TAM from tumour tissue was
applied. Next the gently separation of the tumour from the healthy
muscle, the tumour weight was measured and blended tumour tissue
was suspended in free Serum medium (0.2 mg/2 ml) adding 20 μl of
collagenase (0.1 mg/ml) mixed at 37 °C for 45 min applying continuous
rotation. The tumour lysate was filtered with 70 μm cell strainer in a
50 ml tube and centrifuged 5 min at 0.4 rcf adding 20 ml of PBS. The
red blood cell lysis buffer was added at supernatant for 20 min at RT
and then the solution was centrifuged 5 min at 0.4 rcf adding 20 ml of
PBS. The pellet was suspended to 1 × 106 cells/ml and 1 ml was
transferred to a 5 ml polystyrene tube. After the Fc blocking (Miltenyi
Biotec GmbH) for 5 min at RT, single cell suspensions were obtained
and stained with anti-CD45-VioGreen, anti-F4/80-PE/Vio770 and anti-
CD11b-FITC. Samples were analysed on a BD FACSVerse and analysed
using BD FACSSuite software.
3. Results and discussion
The dynamics of ferumoxytol particles did not appear to change
significantly between suspensions in water and in a model of extra-
cellular media. Fig. 1 shows the 1/T1 NMRD profile of a ferumoxytol
suspension in water (37 °C) and in matrigel (37 °C and 30 °C). Matrigel
is the trade name for a gelatinous protein mixture secreted by En-
gelbreth-Holm-Swarm (EHS) mouse sarcoma cells. It is considered a
good model of the extracellular matrix and is used as a substrate for cell
cultures [24,40].
Interestingly, the iron relaxivity (the relaxation rate per unit con-
centration, r1 in mM−1 s−1) in both water and matrigel is greater than
25 s−1 mM−1 over the entire range of magnetic fields observed. Several
theories are available to describe relaxation for small and large iron
oxide particles [41–43] and they can provide some insights on the
dynamics of the system.
As described by Roch's heuristic model [44], at high field the re-
laxation rate only depends on τD (translational correlation time) and
the inflection frequency fI corresponds to the condition defined by ωIτD
~1, where ωI = 2πfI. Since τD = r2/D, where D is the water diffusion
coefficient (2.3 × 10−5 cm2 s−1 at 25 °C), and r is the radius of the
particles, the determination of τD from the NMRD profile allows one to
estimate the distance of minimum approach for the water molecules
diffusing at the surface of the particles. This informs on water mobility
in the vicinity of the particle. At very low fields the relaxation rate is
directly proportional to the size of the magnetic core and to the energy
of the crystal anisotropy. The Néel relaxation time τN depends on the
latter and relates to the relaxation of the global magnetic moment of the
particle. Hence the relatively high anisotropy of ferumoxytol magnetic
core provides it with a relatively high relaxivity even at low magnetic
field strengths.
Fig. 1 shows the close similarity between the 1/T1 profiles acquired
in water and in matrigel thus supporting the view that water mobility
(and thus diffusion coefficient) is maintained in both systems despite
the higher viscosity of the latter [25].
3.1. NMRD profiles of murine macrophages (J774) in vitro labelled with
ferumoxytol
Before carrying out in vivo studies, we evaluated the changes in the
relaxivity of ferumoxytol due to intracellular and intra-organelles
compartmentalization (endosomes, lysosomes). To do this we acquired
the NMRD profiles of J774A.1 cell line incubated with ferumoxytol.
J774A.1 are a murine monocyte-derived macrophage cell line, often
used as phagocytic cell models simulating particle uptake occurring in
tumour stroma by TAM [45]. In the case of cellular internalization of
Gd‐based complexes, it has been already reported [46–49] that, upon
increasing the concentration of Gd-complexes in the endosomal com-
partments, a “quenching” effect on the observed relaxivity takes place.
In fact, when the intravesicle concentration of the imaging probe is high
(thus resulting in a very large intravesicle relaxation rate), the exchange
regime between vesicles and cytosol becomes slow with respect to the
differences in relaxivities of the two compartments. Therefore, the re-
laxation rate of the cytosol compartment is only slightly enhanced by
the presence of the entrapped magnetic species. In other words, the
water exchange across the vesicle membrane sensibly limits the re-
laxation rate of the cytosolic water protons compared with the same
amount of probe dissolved in the cytosol.
J774A.1 cells were incubated for 24 h at 37 °C with different con-
centrations of ferumoxytol. For the NMRD profile acquisition, 20 mil-
lion cells were transferred in 5 mm NMR tubes and centrifuged with
1 ml of PBS (phosphate saline buffer) at 0.1 rcf for 5 min. As shown in
Fig. 2, the NMRD profiles of ferumoxytol-labelled J774A.1 cells are
very different from those obtained from a ferumoxytol aqueous solu-
tion. In particular, the relaxivity peak at ca. 8–10 MHz in water is
shifted to lower magnetic field strengths (0.8–1 MHz) as a consequence
of the modification of the diffusion coefficient (D). The model used here
predicts that D can influence both the amplitude and the position of the
R1 peak due to the local increase of water viscosity in the immediate
vicinity of the magnetic nanoparticles, which causes an increase in τD.
Note that increasing the particle size is equivalent to decreasing the
diffusion coefficient D and would shift the relaxivity peak further down
along the frequency axis.
Most importantly, the values taken by the relaxivity profiles for
ferumoxytol-bearing cells are significantly lower than those ones
Fig. 1. 1/T1 NMRD profile of a ferumoxytol solution in water (37 °C) and in
matrigel (37 °C and 30 °C).
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observed for ferumoxytol in neat buffer solution at any magnetic field.
This is due to the occurrence of a relaxivity “quenching” upon fer-
umoxytol compartmentalization in intracellular vesicles (endosomes,
lysosomes) in analogy to what has already been observed with Gd-
complexes [46–49]. When nanoparticles are incubated in a cell sus-
pension, the endo-phagocytic uptake ends up placing them into vesicles
arising from the invagination of the cytosolic membrane [50]. This
locally increases the concentration of particles, which lowers their
overall relaxivity as explained above. Fig. 2 shows that the “quenching”
effect on r1 is inversely proportional to the Fe concentration taken-up
by cells. In fact, an increase of intravesicular Fe concentration corre-
sponds to a more pronounced relaxivity “quenching” effect. From these
results, one may conclude that the contribution to the overall 1H re-
laxation rate generated by intracellular ferumoxytol is markedly
smaller than the value measured when the same amount of magnetic
particles are suspended in the extracellular medium. Moreover, the
acquisition of R1 values at different frequencies allows us to extract
useful information on the localization of magnetic particles that is not
available from measurements carried out at fixed and high magnetic
fields. This finding appears extremely important for monitoring the fate
of labelled cells in vivo.
3.2. Ferumoxytol in melanoma (B16–F10) grafted tumour models
The possibility to characterize ferumoxytol internalization was then
tested in vivo. B16–F10 melanoma cells were implanted in mice leg
(n = 12) following the protocol described in material and methods. The
position of the graft was dictated by the round shape of the detection
coil and its diameter (11 mm) [24]. It is well known that neoformed
vessels of solid tumour show a significantly higher permeability to
nanoparticles that leads to larger accumulation compared with healthy
tissues (EPR effect), hence this model was expected to show large
USPIO contrast. Due to the lack of spatial resolution, NMRD profiles on
living tumour tissues were acquired only when the tumour mass
was>65% of the total leg tissue in order to minimize partial volume
effects. Under this condition, healthy muscle only affects the observed
relaxation rates to a limited extent (Fig. 3A). The selected types of tu-
mours B16–F10 murine melanoma are characterized by a high amount
of macrophages infiltrating the tumour stroma [51–53]. Therefore the
amount of ferumoxytol remaining in the tumour 24 h after the injection
was expected to be high due to an efficient uptake by TAM. Ferumox-
ytol was injected at the dose of 0.5 mmol Fe/kg and the accumulation in
tumour tissues was assessed 3 and 24 h after by measuring T1 at 7 T
(Fig. 3B), followed directly by the acquisition of the NMRD profile in
order to deal with strictly analogue anatomical and functional condi-
tions. A period of 3 h post contrast appeared a good compromise to
maximize the extravasation of the nanoparticles into tumour mean-
while to minimize the macrophages phagocytosis, which is expected to
increase markedly after 24 h. During this time, the clearance of not
internalized nanoparticles takes place [6,7,23,54,55]. The use of a high
magnetic field strength ensured the observation of a fast exchange re-
gime to satisfy the condition |R1in − R1ex|« kin+ kex, where R1in and
R1ex are the intra- and extra-cellular relaxation rates respectively and
kin and kex are the water efflux and influx rates, respectively. This en-
sures that the magnetization recovery remained monoexponential and
that the measurement of the relaxation rate was independent of the
presence of intra and extracellular compartments [24,25,38].
As expected the amount of ferumoxytol measured 24 h after the
injection was significantly lower than that measured at 3 h. In fact, after
24 h most of the ferumoxytol was washed out by the tumour stroma and
the remaining particles were mostly internalized into macrophages.
Fig. 2. NMRD profiles, acquired at 25 °C, of J774A.1 cells labelled with fer-
umoxytol with two different Fe concentration 2.2 (■) and 14.5 (●) mM, re-
spectively. Filled triangles (▲) correspond to the NMRD profile of ferumoxytol
alone dissolved in buffer. The indicated concentrations refer to the Fe con-
centration in the cell pellets measured by ICP-MS. The relaxation rates are
normalized to the residual Fe concentration found in cell pellets measured by
ICP-MS.
Fig. 3. (A) T2-weighted MRI (7 T) of the tumour-bearing mouse (B16–F10
graft). (B) Fe concentration in the B16 tumour tissue at 3 h (mostly extra-
cellular, n = 7) and 24 h (mostly intracellular, n = 11) after ferumoxytol i. v.
administration. Concentrations were calculated starting from T1 data, acquired
at 7 T. Error bars represent the Standard Deviation.
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Fig. 4 shows the R1 values obtained by the monoexponential fitting of
magnetization recovery from 0.01 to 1 MHz of B16–F10 tumour mouse
model at 3 h (n = 6) and 24 h (n = 12) after administration of na-
noparticles.
As expected, a marked relaxation enhancement was observed 3 h
after injection of ferumoxytol at any magnetic field strength. This en-
hancement was quite pronounced both at 1 (+106%) and 0.01 MHz
(+57%). After 24 h the almost complete ferumoxytol wash-out from
the tumour yielded a dramatic decrease of the relaxation enhancement.
In order to isolate the ferumoxytol contribution from the overall re-
laxation rates, the pre-treatment R1 was subtracted to the profiles ac-
quired 3 and 24 h post-ferumoxytol administration (Fig. 5A). For con-
venience we will indicate as ΔR13 h and ΔR124 h the dispersion profile
data resulting from the measurement acquired at 3 h and 24 h post
injection upon subtraction of the pre-injection data.
ΔR124 h exhibited an overall shape that appeared very different from
ΔR13 h: its profile invariantly displayed a positive slope (calculated in
the range 0.01–0.07 MHz) with a maximum around 0.8–1 MHz
(Fig. 6A) similar to the one found for ferumoxytol-labelled J774A.1
macrophages, whereas ΔR13 h yielded negative slopes (calculated in the
range 0.01–0.15 MHz). Thus, the R1 slopes obtained at 3 and 24 h after
ferumoxytol treatment (Fig. 5B) appear as the most significant para-
meter to use since they are unequivocal reporters of the localization of
ferumoxytol nanoparticles. The positive slope observed at 24 h is si-
milar to that observed for J774A.1 incubated with ferumoxytol (Fig. 6)
thus supporting the view that, in vivo and after 24 h, the relaxation
enhancement observed arises essentially from the cellular-entrapped
ferumoxytol. On the contrary, the R1 profile acquired immediately after
dissolving ferumoxytol nanoparticles into the extracellular space of
J774A.1 without incubation at 37 °C (Fig. 6) shows the same behavior
as observed in vivo 3 h after ferumoxytol administration, once sub-
tracted from the profile of untreated cells. Note that the profiles showed
in Fig. 5A are in the range 0.01–1 MHz because the R1 value measured
at 10 MHz deviates from the expected trend. This could be the con-
sequence of the dramatic decrease of T2* induced by iron oxide parti-
cles occurring between 1 and 10 MHz [44] that may cause an error in T1
estimation [56].
Moreover, by plotting ΔR124 h measured at the maximum of the re-
laxation peak (1 MHz, Fig. 5A) as a function of the effective intratumour
Fe concentration as determined at 7 T, one can obtain an average re-
laxivity r1 at this field (r1 = 7 mM−1 s−1) that can be used to determine
the intracellular Fe concentration in unknown samples (Fig. 7).
Thus, supposing a linear behavior for ΔR124 h as shown in Fig. 8, a
semi-quantitative estimation of the fraction of macrophages present in
the tumour 24 h after ferumoxytol injection can be obtained using the
following equation (derived as described in materials and methods):
= + × ×% TAM in tumour tissue ( R 0.41)mmols of Fe per cell 7 10h124 10 (7)
where ΔR124 h is the difference in tissue relaxivities as defined above,
when measured at 1 MHz. The amount of Fe per cell (1.5 × 10−12
mmol of Fe/cell) was measured by Inductively Coupled Mass Spectro-
metry (ICP-MS) in J774A.1 cells incubated for 24 h with ferumoxytol
0.005 mM (Fe concentration). The use of this ferumoxytol concentra-
tion yielded a r1 relaxivity equal to that determined in vivo at the same
magnetic field (1 MHz). Using this equation it was possible to obtain the
fraction of macrophages inside the tumour tissues, ranging from 2.7%
to 21% in the melanoma-bearing animals considered in this study.
These percentages are in good agreement with those ones found in the
literature for melanoma tumours [57]. Moreover, the estimated TAM %
were compared with those obtained by flow cytometry after col-
lagenase digestion on the same tumour tissues [58]. (Table 1) The
agreement of the two methods was assessed by the Bland and Altman
statistical method [59,60] with a confidence level of 95% (see Fig. S2,
supplementary materials).
Fig. 4. NMRD profiles of tumour-bearing mouse legs before (PRE), 3 and 24 h
after (POST) the i. v. injection of ferumoxytol.
Fig. 5. A) ΔR1 curves, obtained by subtracting pre-treatment profiles to the
corresponding post-treatment profiles acquired 3 h (dark gray filled symbols,
n = 6) and 24 h (open symbols, n = 11) after ferumoxytol administration to
mice bearing melanoma tumours. Black squares correspond to the control for
POST and PRE profiles acquired 24 h after the injection of a physiological so-
lution; B) Average Slopes of ΔR1 profiles. Statistical significance was de-
termined by Student's t-test: P = 0.0133 (3 h); P = 0.00003 (24 h)
(***P < 0.01, *P < 0.05).
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3.3. Assessment of ferumoxytol localization in tumour tissue
The results described above needed to be validated by microscopy
to verify that ferumoxytol was indeed internalized by macrophages 24 h
after exposure. Immediately after the NMRD profile acquisition, mice
were sacrificed to carry out histological analysis using the Perls’
(Prussian Blue) stain protocol to assess intratumoural localization of
contrast agent. In Fig. 8, the Perls staining positivity of histological
sections is shown at 3 and 24 h after the injection of ferumoxytol,
compared to control sections. At 3 h after the administration, the dis-
tribution of the Perls stain was largely diffuse with an extracellular
localization, especially in the haemorrhagic area and on the border
between muscle and tumour, indicated with the letter M and T in the
figures, respectively. At 24 h, in the same area, the Perls staining ap-
peared to have a largely dominant intracellular location, more appre-
ciable at high magnification. In particular, in Fig. 8F the Perls stain
positivity is clearly detectable in cytoplasmic area surrounding the
nucleus, as the black arrows indicate.
Fig. 9 shows that the tissue slice distribution of CD68 staining po-
sitivity was comparable with Perls staining accordingly to the iron
nanoparticle localization inside macrophages.
In order to unequivocally demonstrate that the ferumoxytol re-
maining in the tumour tissue 24 h after its injection is taken up only by
TAM, it was necessary to carry out CD68 and Pearls staining on the
same tissue slide. To avoid any interference between Perls staining,
which involves the use of 5% hydrochloric acid solution, and CD68
immuno-detection, a dual-step staining procedure was performed. First
immunohistochemistry for CD68 was carried out and several images
were acquired with optical microscope. Then AEC substrate was com-
pletely removed by dipping the slide in alcohol and xylene. Finally,
Perls staining was performed on the same slide and images of the same
field were acquired. Fig. 10 shows that only macrophages (positive to
CD68 staining) exhibit positivity to Perls staining whereas the re-
maining tumour cells are negative to both staining. The absence of
ferumoxytol internalization by tumour cells was reported also in the
studies published by Daldrup-Link H. E. (2012) [61] and Cao Q. (2018)
[62] performed in different types of tumours.
3.4. Intracellular ferumoxytol relaxivity (mM−1 s−1) estimated by the 2
site eXchange model (2SX)
So far we analysed the magnetization decay using a mono-
exponential model. This may draw some criticisms since the system
studied is a multi-compartmental one. Herein, a more in-depth ap-
proach is carried out with the aim of assessing the intracellular fer-
umoxytol relaxivity. As the vascular space occupies a small tissue
fraction, both healthy and tumour tissues can be approximatively de-
scribed as systems composed of two compartments, one intracellular
and another extracellular. During the time required by a NMR relaxa-
tion measurements or an image acquisition, water can explore both
compartments and the resulting R1 results from a mixing of their re-
laxation rates R1in and R1ex weighted by their respective volume frac-
tions (Vin and Vex). This two-compartments situation is described by the
2SX model, which we will use here to extract quantitative parameters
from the system [31–34]. (Fig. 11).
In the absence of paramagnetic labelling, differences in the relaxa-
tion rates of the two compartments are inversely proportional to the
magnetic field strength, since R1ex has a much less pronounced mag-
netic field dependence with respect to R1in [24,31]. When, at certain
magnetic fields, these differences reach the same order of magnitude as
the exchange rate across the cellular membranes (i.e. |R1in-
R1ex| ~ kin + kex) a biexponential magnetization decay becomes evi-
dent. The occurrence of this condition allows extracting two apparent
contributions, one characterized by the longer and one by the shorter
longitudinal relaxation time. Under these conditions the decay of the
longitudinal magnetization Mz depends not only from the values of R1in
and R1ex but also on how fast water exchange takes place between the
two compartments. It was shown that, at the high magnetic field
strength of clinical scanners, the fulfillment of these conditions may be
reached by adding high concentrations of paramagnetic Gd complexes
to the extracellular compartment [46–49]. Therefore, τin (intracellular
water residence time, 1/kin) and τex (extracellular water residence time,
1/kex) are introduced in the 2SX fitting model of the magnetization
recovery curves [31–34]. Such residence lifetimes are correlated, ac-
cordingly to the mass balance, through the volume fraction values of
the two compartments:× = ×V Vin ex ex in (8)
To get an estimation of the different parameters, MZ recovery was
acquired over an extended number of relaxation delays (n = 32) to
improve the sampling of both fast and slow T1 components while ap-
plying the Saturation Recovery procedure. We have recently shown by
the in vivo acquisition of 1/T1 NMRD profiles of mammary adeno-
carcinoma (on the same prototype FFC-NMR spectrometer used in this
Fig. 6. R1-difference curves, obtained on J774A.1 cells incubated in vitro with
ferumoxytol (0.1 mM) for 24 h (open circles) or J774A.1 cells simply exposed to
ferumoxytol (1 mM) in the external PBS solution without incubation at 37 °C
(black filled squares).
Fig. 7. ΔR124 h measured at 1 MHz as a function of the effective intratumour
[Fe] mM measured at 7 T.
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study) that water exchange rates across the cellular membrane can be
assessed by measuring water T1 over an extended range of magnetic
fields. This result has been achieved, in the absence of paramagnetic
species, thanks to the more pronounced relaxation differences between
two compartments observed at low field [24]. On this basis, the NMRD
profiles of the mouse melanoma tumours acquired just before fer-
umoxytol injection (Fig. 4) were analysed according to the 2SX model,
while fixing the extracellular R1ex to the values obtained at the same
field with matrigel alone. The parameters obtained from the fitting are:
τin = 1.31 ± 0.32 s, Vex = 0.26 ± 0.03. The averaged R1in values
obtained at the different magnetic fields are reported in the supple-
mentary materials (Supplementary Information, Fig. S1).
The administration of ferumoxytol was expected to affect the intra-
and extra-cellular compartments to a different extent depending on its
distribution. In fact, 3 h after the injection, ferumoxytol was mostly
distributed in the extracellular matrix of the tumour and therefore it
was expected to significantly increase R1ex. Conversely, 24 h after, the
remaining contrast agent was localized intracellularly (as demonstrated
by the Perls' Prussian blue staining) and therefore it contributed to
further enhance the R1in term. The high relaxivity of ferumoxytol
(r1 > 30 mM−1s−1 in matrigel) at any applied magnetic field
(0.01–1 MHz) and its relatively high concentration in the extracellular
space reduced the differences of relaxivities between the two com-
partments so that |R1in-R1ex| < kin+ kex. Under this condition, the Mz
decays observed were almost completely monoexponential and did not
depend on the water exchange rate between the two compartments.
Moreover, it was difficult to assume which one was the fast or slow site
to be considered in the 2SX model. On the other hand, the intracellular
localization of ferumoxytol observed 24 h post i. v. simplified the model
Fig. 8. Perls staining of a representative melanoma B16–F10 tumour tissue. (A-C magnification 20×; D-F magnification 40x). A, D: Nuclear Fast Red (NFR) staining
of an untreated control tumour, B, E: NFR and Perls staining 3 h after ferumoxytol injection, C, F: NFR and Perls staining 24 h after ferumoxytol injection. M indicates
muscle tissue, T indicates tumour tissue, the arrows indicates iron deposits inside macrophages. Scale bars, 50 μm. (For interpretation of the references to colour in
this figure legend, the reader is referred to the Web version of this article.)
Table 1
Comparison of TAM determination by flow cytometry
(FACS) and relaxometry (NMRD).









Fig. 9. Comparison between (A) CD68 (cell nuclei
counterstained with haematoxylin) and (B) Pearls
(cell nuclei counterstained with nuclear Fast Red)
staining on two adjacent slices (5 μm) (magnification
40x). T and TR indicate tumour tissue and tumour
rim, respectively. Arrows indicate macrophages.
Scale bars, 25 μm. (For interpretation of the refer-
ences to colour in this figure legend, the reader is
referred to the Web version of this article.)
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because the paramagnetic contribution to relaxation rate did only in-
crease R1in and the intracellular compartment was consistently the one
characterized by the fastest relaxation rates over all the observed
magnetic fields range (0.01–1 MHz).
Then, by fixing R1in, R1ex, Vex and τin at the values determined
above in the absence of any added ferumoxytol, the profiles acquired
24 h after ferumoxytol injection were analysed according to 2SX model
with the aim of assessing the millimolar relaxivity (in mM−1 s−1) of
intracellular ferumoxytol. The ferumoxytol contribution was added to
the relaxivity of the intracellular compartment (the fast-relaxing com-
partment) due to the uptake of iron oxide particles by TAM, as de-
scribed in the literature [10] and demonstrated above by Perls staining.
The iron concentration was calculated from the T1 measurement per-
formed at 7 T (Fig. 4), as described above. Thus, by carrying out the 2SX
analysis of the Mz evolution, it was possible, for the first time to our
knowledge, to calculate the intracellular relaxivity of a super-
paramagnetic particle such as ferumoxytol in vivo on a tumour animal
model. Interestingly, the curves obtained by plotting r1 against the
applied magnetic field strength (Fig. 12) showed an overall shape that
appeared completely different with respect to those obtained from
ferumoxytol in water, buffer and matrigel, as shown in Fig. 1. In fact,
the relaxation rates displayed a kind of profile reminiscent of the one
found from ferumoxytol-labelled J774A.1 macrophages. These extra-
polated R1in profiles shape (Fig. 12) confirmed the intra-organelles lo-
calization as surmised from the less rigorous monoexponential analysis
of Mz decay reported in the previous paragraph.
4. Conclusions
From these results, one can conclude that the characteristics of the
NMRD profile immediately reports on the intra- or extra-cellular locali-
zation of the contrast agent investigated (ferumoxytol). This information
could not be obtained from measurements at a single magnetic field and
opens new horizons for the field of cell-tracking applications. From R1
measurements acquired before and after ferumoxytol injection it was
possible to obtain a good estimation of the fraction of TAM in the tissues,
a fundamental parameter for tumour characterization and treatment
selection, despite the lack of spatial resolution of the prototype FFC-NMR
instrumentation used in this work. Low-field FFC has recently been de-
monstrated as a possible technology for application in dedicated MRI
scanners [21] thus supporting the view that new biomarkers, such us the
intracellular water residence time, may be added to the armory of in vivo
imaging parametres.
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